UNION therapeutics appoints drug development leader Dr. Peter Kristensen to its Board of Directors
· Dr. Peter Kristensen, MD, DMSc, EMBA, appointed new member of UNION’s Board of Directors, bringing more than 25 years of expertise from drug development and regulatory approval from pharmaceutical companies · Strengthening of the Board of Directors with late-stage drug development expertise follows read-out of three Phase 2/2b studies with orismilast and prior to initiation of Phase 3 studies with orismilast in atopic dermatitis (AD) Hellerup, Denmark, August 6, 2024 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused